EM1712E "Well Differentiated Neuroendocrine Tumors past, present and future
The purpose of this presentation is to provide a summary and discussion of the current definition, epidemiology, pathophysiology, prognostic factors, new imaging modalities and level 1 evidence systemic therapies for patients with well differentiated pancreatic and non-pancreatic neuroendocrine tumors. A list of priorities for future clinical research is mentioned at the end of the presentation.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Understand the definition and epidemiology of well differentiated neuroendocrine tumors.
- Describe the role of somatostatin, somatostatin receptors and serotonin in well differentiated neuroendocrine tumors.
- Describe clinical and molecular prognostic factors in well differentiated neuroendocrine tumors.
- Understand the role of 68Gallium Dodatate PET scan in the evaluation of patients with well differentiated neuroendocrine tumors.
- Describe level 1 evidence systemic therapies for metastatic well differentiated neuroendocrine tumors.
- Describe the role of telotristat for the treatment of carcinoid diarrhea.
Yull E. Arriaga, M.D.
Division of Hematology / Oncology
Dr. Arriaga is focused on giving his patients better cancer treatments and improving their quality of life. He believes that a multidisciplinary approach is the best way to treat patients with cancer. He specializes in Genitourinary (GU) and Gastrointestinal (GI) Medical Oncology. He is vice-chair of the Data and Safety Monitoring Committee (DSMC) at the Simmons Cancer Center. He is the principal investigator of several clinical trials in genitourinary medical oncology.
- 1.00 AMA